Endocrinology Advisor3d
Novo Nordisk’s Wegovy, Ozempic No Longer in Short Supply, According to FDA
The Food and Drug Administration has determined that the shortage of Wegovy® (semaglutide) and Ozempic® (semaglutide) is resolved.
England subsidises drugs like Ozempic for weight loss. Could Australia follow?
If Australia followed England’s lead and listed drugs such as Wegovy on the PBS for weight loss, this could bring the cost ...
pharmaphorum2d
Novo Nordisk moves chronic kidney disease drug ziltivekimab into phase 3
Novo Nordisk has announced plans to move its ziltivekimab into phase 3 clinical development in atherosclerosis with chronic kidney disease after a mid-stage trial met its main goal.
pharmaphorum1d
Beyond glucose in type 2 diabetes: how Novo Nordisk is looking to address chronic kidney disease
In this regard Novo Nordisk is leading the way. We've become increasingly committed to chronic conditions that include cardiovascular disease and chronic kidney disease – the reason being ...
Irish Examiner on MSN1d
On the rebound: What are the long-term risks of Ozempic?
Ahead of World Obesity Day, we examine the impact of the game-changing drugs that control appetite. Increasingly being taken ...
Lexaria Bioscience Corp.: The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience
Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
The GLP-1 Revolution — How Private Equity Investors Are Capitalizing
The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...
Insider Monkey5d
Novo Nordisk A/S (NVO): Among Renaissance Technologies Portfolio’s Top Stock Picks
In this article, we are going to take a look at where Novo Nordisk A/S (NYSE ... especially for chronic disease management. Wall Street analysts remain bullish on the stock, with a consensus ...